STOCK TITAN

Karyopharm Announces Upcoming Virtual Investor Conference Participation

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced participation by CEO Richard Paulson in two virtual investor conferences. The Wedbush PacGrow Healthcare Virtual Conference will take place on August 10, 2021, at 8:35 AM ET. The Canaccord Genuity 41st Annual Growth Conference is set for August 12, 2021, at 3:30 PM ET. Live webcasts will be available on the company's website, with replays archived for 30 days. Karyopharm focuses on pioneering cancer therapies and is known for its lead drug, XPOVIO®.

Positive
  • None.
Negative
  • None.

NEWTON, Mass., Aug. 3, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Richard Paulson, President and Chief Executive Officer, will participate on a speaker panel at the 2021 Wedbush PacGrow Healthcare Virtual Conference titled, "Building Back a Better Commercial Infrastructure – Selling in COVID Times" and participate in a fireside chat at the Canaccord Genuity 41st Annual Growth Conference. Details regarding these upcoming virtual investor conferences are below.

2021 Wedbush PacGrow Healthcare Virtual Conference
Date: Tuesday, August 10, 2021
Time: 8:35 AM Eastern Time

Canaccord Genuity 41st Annual Growth Conference
Date: Thursday, August 12, 2021
Time: 3:30 PM Eastern Time

A live webcast of the panel and fireside chat can be accessed under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations. A replay of the webcasts will be archived on the Company's website for 30 days following the panel and fireside chat.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (NASDAQ: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of first-in-class drugs directed against nuclear export for the treatment of cancer and other diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm's lead compound, XPOVIO® (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade® (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. NEXPOVIO® (selinexor) has also been granted conditional marketing authorization in combination with dexamethasone for adult patients with heavily pretreated multiple myeloma by the European Commission. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. For more information, please visit www.karyopharm.com.

Cision View original content:https://www.prnewswire.com/news-releases/karyopharm-announces-upcoming-virtual-investor-conference-participation-301346572.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

What is Karyopharm Therapeutics' involvement in the upcoming Wedbush PacGrow Healthcare Virtual Conference?

Karyopharm Therapeutics announced that CEO Richard Paulson will participate in a panel at the Wedbush PacGrow Healthcare Virtual Conference on August 10, 2021.

When will Karyopharm Therapeutics participate in the Canaccord Genuity 41st Annual Growth Conference?

Karyopharm Therapeutics will participate in the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021.

Where can I watch the Karyopharm Therapeutics conferences online?

Live webcasts of Karyopharm Therapeutics' events will be available on their website.

What is the significance of Karyopharm Therapeutics' lead drug XPOVIO®?

XPOVIO® is Karyopharm's lead compound approved for treating multiple hematologic malignancies and is known for its role in nuclear export inhibition.

How does Karyopharm Therapeutics develop its cancer therapies?

Karyopharm focuses on discovering and developing first-in-class drugs that inhibit nuclear export, targeting cancer and other diseases.

Karyopharm Therapeutics Inc.

NASDAQ:KPTI

KPTI Rankings

KPTI Latest News

KPTI Stock Data

82.52M
117.36M
6.15%
50%
15.11%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NEWTON